James P. Boylan - 10 Jun 2025 Form 4 Insider Report for Zenas BioPharma, Inc. (ZBIO)

Role
Director
Signature
By: /s/ Jeffrey Held, Attorney-in-Fact
Issuer symbol
ZBIO
Transactions as of
10 Jun 2025
Net transactions value
$0
Form type
4
Filing time
12 Jun 2025, 16:36:42 UTC
Previous filing
13 Feb 2025
Next filing
27 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Boylan James P Director C/O ZENAS BIOPHARMA, INC., 852 WINTER ST., SUITE 250, WALTHAM By: /s/ Jeffrey Held, Attorney-in-Fact 12 Jun 2025 0001953094

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZBIO Stock Option (Right to Buy) Award $0 +18,500 $0.000000 18,500 10 Jun 2025 Common Stock 18,500 $11.94 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 100% of the underlying shares of common stock on June 10, 2026, the first anniversary of the vesting commencement date, subject to continued service.
F2 The reporting person holds the stock option, and the shares underlying the option, for the benefit of Enavate Sciences, LP. Accordingly, the reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, if any.